BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016;30:242-52. [PMID: 26864543 DOI: 10.1177/0269881116628440] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 12.6] [Reference Citation Analysis]
Number Citing Articles
1 Sobreira G, Oliveira J, Brissos S. Vortioxetine-induced manic mood switch in patient with previously unknown bipolar disorder. Braz J Psychiatry 2017;39:86. [PMID: 28273272 DOI: 10.1590/1516-4446-2016-2113] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Chokka P, Ge H, Bougie J, Ettrup A, Clerzius G. Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study. Ther Adv Psychopharmacol 2021;11:20451253211013148. [PMID: 34025982 DOI: 10.1177/20451253211013148] [Reference Citation Analysis]
3 [DOI: 10.1101/2020.06.05.135996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
5 Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat 2019;15:1249-58. [PMID: 31190831 DOI: 10.2147/NDT.S199746] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
6 Frampton JE. Vortioxetine: A Review in Cognitive Dysfunction in Depression. Drugs 2016;76:1675-82. [DOI: 10.1007/s40265-016-0655-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
7 Kingsberg SA, McElroy SL, Clayton AH. Evaluation of Flibanserin Safety: Comparison with Other Serotonergic Medications. Sex Med Rev 2019;7:380-92. [PMID: 30803922 DOI: 10.1016/j.sxmr.2018.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology 2017;27:773-81. [DOI: 10.1016/j.euroneuro.2017.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
9 Brender R, Mulsant BH, Blumberger DM. An update on antidepressant pharmacotherapy in late-life depression. Expert Opin Pharmacother 2021;:1-9. [PMID: 33910422 DOI: 10.1080/14656566.2021.1921736] [Reference Citation Analysis]
10 McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017;13:2913-9. [PMID: 29238196 DOI: 10.2147/NDT.S150589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
11 Jacobsen P, Zhong W, Nomikos G, Clayton A. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. J Sex Med 2019;16:1638-49. [PMID: 31405765 DOI: 10.1016/j.jsxm.2019.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
12 Inoue T, Nishimura A, Sasai K, Kitagawa T. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial: Vortioxetine in Japanese MDD patients. Psychiatry Clin Neurosci 2018;72:103-15. [DOI: 10.1111/pcn.12623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Findling RL, Robb AS, DelBello MP, Huss M, McNamara NK, Sarkis EH, Scheffer RE, Poulsen LH, Chen G, Lemming OM, Auby P. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. J Child Adolesc Psychopharmacol 2018;28:47-54. [PMID: 29035574 DOI: 10.1089/cap.2017.0047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Mahableshwarkar AR, Affinito J, Reines EH, Xu J, Nomikos G, Jacobsen PL. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. CNS Spectr 2020;25:352-62. [PMID: 31199210 DOI: 10.1017/S109285291900097X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. J Affect Disord 2018;229:421-8. [PMID: 29331703 DOI: 10.1016/j.jad.2017.12.056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
16 Baldwin DS, Hou R, Gordon R, Huneke NT, Garner M. Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets. CNS Drugs 2017;31:307-17. [PMID: 28303465 DOI: 10.1007/s40263-017-0423-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
17 Xiong HL, Cao JL, Shen CG, Ma J, Qiao XY, Shi TS, Ge SX, Ye HM, Zhang J, Yuan Q, Zhang TY, Xia NS. Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro. Front Pharmacol 2020;11:609592. [PMID: 33613282 DOI: 10.3389/fphar.2020.609592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Siwek M, Chrobak AA, Gorostowicz A, Krupa AJ, Dudek D. Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review. Pharmaceuticals (Basel) 2021;14:451. [PMID: 34064611 DOI: 10.3390/ph14050451] [Reference Citation Analysis]
19 Danielak D. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients? Expert Opin Pharmacother 2021;22:1167-77. [PMID: 33650935 DOI: 10.1080/14656566.2021.1880567] [Reference Citation Analysis]
20 Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder: Vortioxetine for major depression. Psychiatry Clin Neurosci 2018;72:64-72. [DOI: 10.1111/pcn.12565] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
21 Li Y, Pehrson AL, Oosting RS, Gulinello M, Olivier B, Sanchez C. A study of time- and sex-dependent effects of vortioxetine on rat sexual behavior: Possible roles of direct receptor modulation. Neuropharmacology 2017;121:89-99. [DOI: 10.1016/j.neuropharm.2017.04.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Nierenberg A, Loft H, Olsen C. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. Journal of Affective Disorders 2019;250:35-42. [DOI: 10.1016/j.jad.2019.02.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
23 Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. Journal of Affective Disorders 2016;206:140-50. [DOI: 10.1016/j.jad.2016.07.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 6.6] [Reference Citation Analysis]
24 D’andrea G, De Ronchi D, Giaccotto L, Albert U. Vortioxetine treatment-emergent mania in the elderly: a case report. Australas Psychiatry 2019;27:413-413. [DOI: 10.1177/1039856219839471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Vieta E, Florea I, Schmidt SN, Areberg J, Ettrup A. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2019;34:153-60. [PMID: 31094901 DOI: 10.1097/YIC.0000000000000271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
26 Segura-Garcia C, Rania M, Carbone EA, de Filippis R, Aloi M, Caroleo M, Grasso G, Calabrò G, Fazia G, Staltari FA, Falvo A, Pugliese V, Gaetano R, Steardo L Jr, De Fazio P. Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression. Front Psychiatry 2021;12:635502. [PMID: 33815170 DOI: 10.3389/fpsyt.2021.635502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol 2018;32:1086-97. [PMID: 30047820 DOI: 10.1177/0269881118788826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
28 Salagre E, Grande I, Solé B, Sanchez-moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Revista de Psiquiatría y Salud Mental (English Edition) 2018;11:48-59. [DOI: 10.1016/j.rpsmen.2018.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
29 Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. [PMID: 28677828 DOI: 10.1002/14651858.CD011520.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
30 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
31 Vieta E, Loft H, Florea I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. European Neuropsychopharmacology 2017;27:877-84. [DOI: 10.1016/j.euroneuro.2017.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
32 Frederiksen T, Smith RL, Wollmann BM, Areberg J, Molden E. Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data. Clin Pharmacokinet 2021. [PMID: 34121163 DOI: 10.1007/s40262-021-01029-7] [Reference Citation Analysis]
33 Shweiki S, Diav-Citrin O. Pregnancy outcome after first trimester exposure to vortioxetine: A case series. Birth Defects Res 2021;113:511-5. [PMID: 33463081 DOI: 10.1002/bdr2.1864] [Reference Citation Analysis]
34 Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study. Int Clin Psychopharmacol 2020;35:305-12. [PMID: 32784346 DOI: 10.1097/YIC.0000000000000326] [Reference Citation Analysis]
35 Mcelroy SL, Guerdjikova AI, Mori N, Keck PE. Managing comorbid obesity and depression through clinical pharmacotherapies. Expert Opinion on Pharmacotherapy 2016;17:1599-610. [DOI: 10.1080/14656566.2016.1198776] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
36 Borhannejad F, Shariati B, Naderi S, Shalbafan M, Mortezaei A, Sahebolzamani E, Saeb A, Hosein Mortazavi S, Kamalzadeh L, Aqamolaei A, Ali Noorbala A, Namazi‐shabestari A, Akhondzadeh S. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double‐blind randomized trial. J Clin Pharm Ther 2020;45:804-11. [DOI: 10.1111/jcpt.13177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord 2018;227:803-9. [PMID: 29673132 DOI: 10.1016/j.jad.2017.11.053] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
38 Zareifopoulos N, Papatheodoropoulos C. Effects of 5-HT-7 receptor ligands on memory and cognition. Neurobiol Learn Mem 2016;136:204-9. [PMID: 27780766 DOI: 10.1016/j.nlm.2016.10.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
39 Alcántara Montero A, Pacheco de Vasconcelos SR. Role of vortioxetine in the treatment of neuropathic pain. Rev Esp Anestesiol Reanim 2021:S0034-9356(21)00162-6. [PMID: 34243960 DOI: 10.1016/j.redar.2021.04.001] [Reference Citation Analysis]
40 Calvi A, Fischetti I, Verzicco I, Belvederi Murri M, Zanetidou S, Volpi R, Coghi P, Tedeschi S, Amore M, Cabassi A. Antidepressant Drugs Effects on Blood Pressure. Front Cardiovasc Med 2021;8:704281. [PMID: 34414219 DOI: 10.3389/fcvm.2021.704281] [Reference Citation Analysis]
41 Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
42 Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Curr Med Res Opin 2020;36:875-82. [PMID: 31990207 DOI: 10.1080/03007995.2020.1723072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
43 Villas Boas GR, Boerngen de Lacerda R, Paes MM, Gubert P, Almeida WLDC, Rescia VC, de Carvalho PMG, de Carvalho AAV, Oesterreich SA. Molecular aspects of depression: A review from neurobiology to treatment. Eur J Pharmacol 2019;851:99-121. [PMID: 30776369 DOI: 10.1016/j.ejphar.2019.02.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
44 Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder. Psychiatry Clin Neurosci 2020;74:140-8. [PMID: 31725942 DOI: 10.1111/pcn.12956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
45 Miao J, Wang G, Hou J, Areberg J, Zhao Y, Højer AM, Ettrup A. Pharmacokinetics and Safety of Vortioxetine in the Chinese Population. Adv Ther 2019;36:3134-46. [PMID: 31552551 DOI: 10.1007/s12325-019-01092-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Gill H, Gill B, El‐halabi S, Chen‐li D, Lipsitz O, Rosenblat JD, Van Rheenen TE, Rodrigues NB, Mansur RB, Majeed A, Lui LMW, Nasri F, Lee Y, Mcintyre RS. Antidepressant Medications and Weight Change: A Narrative Review. Obesity 2020;28:2064-72. [DOI: 10.1002/oby.22969] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
47 Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord 2021;283:472-9. [PMID: 33516560 DOI: 10.1016/j.jad.2020.11.106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust 2020;212:329-34. [PMID: 32172535 DOI: 10.5694/mja2.50522] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
49 Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr 2019;24:616-27. [PMID: 30802419 DOI: 10.1017/S1092852919000786] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]